Sugi Predict

Sugi Predict / Compounds / Acetic Acid Phenyl Ester

Acetic Acid Phenyl Ester

Acetic Acid Phenyl Ester

SCHEMBL248164

CC(=O)Oc1ccccc1.CO

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 2/20 0.69
▸ MAPT P10636 4/20 0.64
▸ ALDH1A1 P00352 3/20 0.64
▸ GAA P10253 3/20 0.64
▸ HSP90AA1 P07900 1/20 0.64
▸ LMNA P02545 4/20 0.60
▸ CYP3A4 P08684 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.55
▸ BACE1 P56817 1/20 0.55
▸ TDP1 Q9NUW8 2/20 0.54
▸ POLB P06746 1/20 0.54
▸ PKM P14618 1/20 0.54
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ KDM4E B2RXH2 2/20 0.52
▸ ESR1 P03372 2/20 0.52
▸ TSHR P16473 2/20 0.52
▸ ITGB3 P05106 1/20 0.52
▸ ITGA2B P08514 1/20 0.52
▸ HMGB1 P09429 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid Phenyl Ester SCHEMBL6422166 0.97 ELANE (0.72) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL35500 0.97 ELANE (0.72) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL181469 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL1404134 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL4343067 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL11787346 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL11483885 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL388843 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL1309661 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1
Acetic Acid Phenyl Ester SCHEMBL9154639 0.95 ELANE (0.69) ELANEMAPTALDH1A1GAAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140350301-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2014-11-27 — — US claimed
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2013-06-27 — — US claimed
US-20140350301-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2014-11-27 — — US disclosed
US-20140323727-A1 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2014-10-30 — — US disclosed
US-20130317220-A1 NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF ACTAVIS GROUP PTC EHF (IS) 2013-11-28 — — US disclosed
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2013-06-27 — — US disclosed
US-20130150577-A1 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2013-06-13 — — US disclosed
EP-2588441-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR Actavis Group Ptc Ehf (IS) 2013-05-08 — — EP disclosed
EP-2560939-A2 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES Actavis Group Ptc Ehf (IS) 2013-02-27 — — EP disclosed
WO-2012001531-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2012-01-05 — — WO disclosed
WO-2011132083-A2 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2011-10-27 — — WO disclosed
CN-1724532-A Colorant compound XEROX CORP (US) 2006-01-25 — — CN disclosed
US-5385923-A Treatment of degenerative diseases STERLING WINTHROP INC. (US) 1995-01-31 — — US disclosed
US-4212989-A ARYL ESTER SOLVENTS USED IN CATALYTIC CARBONYLATION FO ALCOHOLS MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1980-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317220-A1 NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF TBXAS1, TBXA2R, THPO ELANE 4706/4885MAPT 3625/4885ALDH1A1 194/4885
US-20140350301-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR THPO, P2RY4, TBXA2R ELANE 4586/4885MAPT 3525/4885ALDH1A1 1717/4885
US-20140323727-A1 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES THPO, P2RY4, TPMT ELANE 4806/4885MAPT 2739/4885ALDH1A1 2075/4885
US-20130150577-A1 NOVEL PROCESS FOR PREPARING PHENYLCYCLOPROPYLAMINE DERIVATIVES USING NOVEL INTERMEDIATES THPO, P2RY4, TPMT ELANE 4806/4885MAPT 2739/4885ALDH1A1 2075/4885
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR THPO, P2RY4, TBXA2R ELANE 4586/4885MAPT 3525/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.